Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. (Q46635180)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424138%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

title

Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424138%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424138%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

author name string

Anouk C Vedder

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424138%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Frank Breunig

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424138%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Wilma E Donker-Koopman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424138%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Kevin Mills

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424138%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Elisabeth Young

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424138%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Bryan Winchester

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424138%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Ineke J M Ten Berge

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424138%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Johanna E M Groener

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424138%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Christoph Wanner

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424138%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Carla E M Hollak

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424138%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

publication date

18 April 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424138%20AND%20SRC:MED&resulttype=core&format=json

Molecular Genetics and Metabolism

6 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424138%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

volume

94

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424138%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

page(s)

319-325

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424138%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424138%20AND%20SRC:MED&resulttype=core&format=json

Fabry's Disease: Alpha-Galactosidase Deficiency

6 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

Clinical benefit of enzyme replacement therapy in Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

Monitoring enzyme replacement therapy in Fabry disease--role of urine globotriaosylceramide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

Immunogenicity of therapeutic proteins: clinical implications and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

Monitoring of Gaucher patients with a novel chitotriosidase assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

Immunoquantification of alpha-galactosidase: evaluation for the diagnosis of Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

Agalsidase alfa--a preparation for enzyme replacement therapy in Anderson-Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

Enzyme-replacement therapy for Anderson-Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.03.003

10.1016/J.YMGME.2008.03.003

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18424138%20AND%20SRC:MED&resulttype=core&format=json

release_ncbliny3brd4ren4vlz3kzosjy

6 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ncbliny3brd4ren4vlz3kzosjy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference